Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) released a new CEO Corner segment featuring President and CEO Brad Hauser. The update highlights growing global scientific and clinical recognition for its nerve-sensing and transvascular denervation platform, including 13 abstract acceptances, nine podium and four poster presentations, across leading conferences.
The technology, honored with a top Cardiovascular Innovation Award at CRT, is presented as having potential to transform treatment of complex conditions such as pancreatic cancer pain and to support physician adoption, future clinical trials, partnerships, reimbursement discussions, and a planned U.S. clinical study.
Positive
- 13 abstract acceptances since last fall, including 9 podium and 4 poster presentations
- Recognition at major scientific forums including TCT, CRT, SIR, and ASCO
- Top Cardiovascular Innovation Award at CRT for the technology platform
- Platform positioned to support future clinical trials and strategic partnerships
- Real-time nerve sensing and targeted therapy approach for conditions such as pancreatic cancer pain
- Planned U.S. clinical study supported by growing scientific and clinical recognition
Negative
- None.
News Market Reaction – AMIX
In the Jun 10 session, AMIX declined 6.47%, reflecting a notable negative market reaction. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Access the segment here
THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser.
As part of the segment, Mr. Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. Mr. Hauser highlighted that since last fall, Autonomix has secured 13 abstract acceptances, including nine podium presentations and four poster presentations at major scientific forums such as Transcatheter Cardiovascular Therapeutics (TCT), Cardiovascular Research Technologies (CRT), Society of Interventional Radiology (SIR), and American Society of Clinical Oncology Annual Meeting (ASCO). He emphasized that these peer-reviewed recognitions, including a top Cardiovascular Innovation Award at CRT, recognize the novelty, rigor, and potential impact of Autonomix’s technology platform. The segment also outlined how the Company’s real-time nerve sensing and targeted therapy approach could transform treatment for complex conditions such as pancreatic cancer pain, while supporting physician adoption, future clinical trials, strategic partnerships, reimbursement discussions, and the Company’s planned U.S. clinical study.
The latest segment is available on the CEO Corner section of the Company’s website (autonomix.com) and social media channels.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company's planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, and reimbursement discussions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
